"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...
- Malignant hyperthermia (see WARNINGS).
- Motor activity exemplified by movements of various muscle groups and/or seizures may be encountered with deep levels of ETHRANE (enflurane, USP) anesthesia, or light levels with hypocapnia.
- Hypotension, respiratory depression, and hypoxia have been reported.
- Arrhythmias, shivering, nausea and vomiting have been reported.
- Elevation of the white blood count has been observed.
- Mild, moderate and severe liver injury, including hepatic failure, may rarely follow anesthesia with enflurane. Serum transaminases may be increased and histologic evidence of injury may be found. The histologic changes are neither unique nor consistent. In several of these cases, it has not been possible to exclude enflurane as the cause or as a contributing cause to liver injury. The incidence of unexplained hepatotoxicity following the administration of enflurane is unknown, but it appears to be rare and not dose related.
ETHRANE (enflurane, USP) has also been associated with perioperative hyperkalemia (see WARNINGS).
The following adverse events have been identified during post-approval use of ETHRANE (enflurane, USP). Due to the spontaneous nature of these reports, the actual incidence and relationship of ETHRANE (enflurane, USP) to these events cannot be established with certainty.
Cardiac Disorders: Cardiac arrest
Hepatobiliary Disorders: Hepatic necrosis, Hepatic failure
Read the Ethrane (enflurane) Side Effects Center for a complete guide to possible side effects
The action of nondepolarizing relaxants is augmented by enflurane. Less than the usual amounts of these drugs should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of enflurane than when halothane or nitrous oxide with a balanced technique are used.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/5/2016
Additional Ethrane Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.